›› KLIFOVET › EXPERTISE › PUBLICATIONS

We thank Zoetis for their acknowledgement in this publication: A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis

Abstract Objective Bedinvetmab is a canine monoclonal antibody targeting nerve growth factor. This study evaluated the efficacy and safety of bedinvetmab for alleviation of pain associated with osteoarthritis in dogs. Study design Double-blind, randomized, multicentre, placebo-controlled study. Animals Client-owned dogs (n = 287) with osteoarthritis. Methods Dogs were randomized (1:1) to subcutaneous injection with placebo (saline, n = 146) or bedinvetmab (0.5-1.0 mg/kg, n = 141) administered monthly. After 3 months, 89 bedinvetmab-treated dogs that responded positively based on owner and veterinarian assessments were administered up to six additional doses of bedinvetmab in a single-armed open-label continuation phase. The primary efficacy end point was treatment success based on the owner-assessed canine brief pain inventory (CBPI) on day 28. Treatment success was defined as >= 1 reduction in pain severity score (0e10) and >= 2 in pain interference score (0-10). Results Percentage treatment success was significantly greater in the bedinvetmab group than in the placebo group from day 7 through all assessed time points (p <= 0.0025). On day 28, 43.5% of dogs achieved treatment success with bedinvetmab compared with placebo (16.9%) (p = 0.0017). Treatment success continued through days 56 (50.8%) and 84 (48.2%) in the bedinvetmab group and was < 25% in the placebo group at all time points. Sustained efficacy was demonstrated in the continuation phase. Adverse health events occurred at similar frequencies in both groups. They were considered typical for a population of dogs with osteoarthritis and not related to study treatment. Treatment with bedinvetmab demonstrated a significant effect on all three components of CBPIdpain interference, pain severity, quality of life. Conclusions and clinical relevance This study demonstrated the effectiveness and safety of bedinvetmab administered monthly for up to 9 months at 0.5e1.0 mg kge1 for alleviation of pain associated with canine osteoarthritis.

DATE » 22.08.2021

AUTHORS » Maria J Corrala, Hilde Moyaerta, Tiago Fernandesa, Monica Escaladaa, Jezaniah Kira S Tenab, Rodney R Waltersb & Michael R Stegemanna aVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium bVeterinary Medicine Research and Development, Zoetis Inc., Kalamazoo, MI, USA

PUBLISHED » Veterinary Anaesthesia and Analgesia 2021, 48, 943-955
https://doi.org/10.1016/j.vaa.2021.08.001